US equities |
NVDA $240.68 ▲+0.75% SPCX $173.69 ▲+1.52% MU $1,064.71 ▲+0.07% MRVL $280.40 ▲+3.38% AMD $655.42 ▲+3.75% INTC $114.35 ▼-1.59% SNDK $1,669.83 ▼-2.01% AVGO $377.70 ▲+4.19%
FinancialContent

Vor Biopharma Inc. - Common Stock (NQ:VOR)

18.43 -0.15 (-0.80%)
Delayed Quote Updated: 12:55 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vor Biopharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
News headline image
The Latest Analyst Ratings for Vor Biopharma ↗
 
Via Benzinga
News headline image
What 11 Analyst Ratings Have To Say About Vor Biopharma ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  During Tuesday's session, 275 companies made new 52-week lows. 
Via Benzinga
News headline image
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
News headline image
8 Analysts Have This to Say About Vor Biopharma ↗
 
Via Benzinga
News headline image
Vor Biopharma: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Where Vor Biopharma Stands With Analysts ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  During the Friday's sesion, 157 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
News headline image
Truist Securities Maintains Buy Rating for Vor Biopharma: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  On Thursday, 128 companies set new 52-week lows. 
Via Benzinga
News headline image
Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference
From Vor Biopharma
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  Wednesday's session saw 43 companies set new 52-week lows. 
Via Benzinga
News headline image
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
Vor Bio's Trem-cel Shows Early Encouraging Data In Leukemia Patients ↗
Vor Biopharma Inc (NASDAQ: VOR) presented updated data from patients treated in the VBP101 Phase 1/2a study of trem-cel (formerly VOR33) in  
Via Benzinga
News headline image
Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in the Goldman Sachs Healthcare Conference
From Vor Biopharma
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023 ↗
 
Via Benzinga
News headline image
Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
News headline image
Dow Rises 50 Points; Oxford Industries Shares Plunge ↗
U.S. stocks pared some losses toward the end of trading, with the Dow Jones and S&P 500 turning higher on Friday. The Dow traded up 0.16% to 32,156.53 while the NASDAQ fell 0.16% to 11,768.17. The S&P... 
Via Benzinga
News headline image
Why Scholastic Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Near Intelligence Inc. (NASDAQ: NIR) shares climbed 53.1% to $16.50. 
Via Benzinga
News headline image
Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Biopharma's Leukemia Cell Exhibits Favorable Engraftment Five Months Post-Transplant ↗
 
Via Benzinga
News headline image
First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference
From Vor Biopharma
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >